Aldosterone may be the hidden culprit in hard-to-treat hypertension, offering new hope for targeted therapies.
Expert Interviews
Advertisement
Deepak Bhatt, MD, discusses EMPACT-MI findings on empagliflozin’s kidney safety and heart failure benefits after ACS.
AI-powered cardiac MRI shows how aging impacts heart structure—and reveals hidden risks from common conditions.
Black patients face higher amputation risk from PAD due to late CLTI care and limited access to revascularization.
ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
BMAL1-HIF2α link explains why AM heart attacks hit harder—new findings may lead to time-based cardioprotective therapies.
AI-driven ECGs are transforming heart failure care—enabling early detection, cutting costs, and expanding access.
Dr. Payal Kohli dives into new tech and AI reshaping how we diagnose and manage hypertension.
Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter.
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
Advertisement